The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Nanoparticulate drug delivery systems for cancer chemotherapy
Open accessAbstract
Nanoparticles (NPs) are, in general, colloidal particles, less than 1000 nm, that can be used for better drug delivery and prepared either by encapsulating the drug within a vesicle and or by dispersing the drug molecules within a matrix. Nanoparticulate drug delivery systems have been extensively studied in recent years for spatial and temporal delivery, especially in tumour and brain targeting. NPs have great promise for better drug delivery as found in both pharmaceutical and clinical research. As a drug carrier, NPs have significant advantages like better bioavailability, systemic stability, high drug loading, long blood circulation time and selective distribution in the organs/tissues with longer half life. The selective targeting of NPs can be achieved by the enhanced permeability and retention effect (EPR-effect), attaching specific ligands, or by making selective distribution due to change of the physiological conditions of specific systems like nature, pH, temperature, etc. It has been observed that drug-loaded NPs can have selective distribution to organs/tissues using different types of and proportions of polymers. The current aim of researchers is to prepare NPs that are long-lived with and that demonstrate the appropriate selective distribution for better therapy and thus improved clinical outcomes. Nanoparticulate drug delivery systems have the potential to deliver a drug to the target site with specificity and to maintain the desired concentration at the site for the intended time without untoward effects. In this review article, the methods for the preparation of NPs, their characterization, biodistribution, and pharmacokinetic characteristics are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Lipid nanoparticles for improved topical application of drugs for skin diseases☆
SCHAFERKORTING, M., MEHNERT, W., & KORTING, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.006 · Cited by 614
Gill, S., Löbenberg, R., Ku, T., Azarmi, S., Roa, W., & Prenner, E. J. (2007) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2007.015 · Cited by 118 · cited 4×
“It is expected that within 10 years, 50% of all drug delivery and design approaches may be shifted to Nanoparticulate Drug Delivery Systems (NPDDS) technology (Gill et al. 2007).”
BackgroundInfluential
Cited by
Progress and challenges towards targeted delivery of cancer therapeutics
Rosenblum, D., Joshi, N., Tao, W., Karp, J. M., & Peer, D. (2018) · Nature Communications · doi:10.1038/s41467-018-03705-y · Cited by 2,220
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F., & Farokhzad, O. C. (2012) · Chemical Society Reviews · doi:10.1039/c2cs15344k · Cited by 1,730
Nanoparticles for Cancer Therapy: Current Progress and Challenges
Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069
Moradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Design of Nanoparticle-Based Carriers for Targeted Drug Delivery
Yu, X., Trase, I., Ren, M., Duval, K., Guo, X., & Chen, Z. (2016) · Journal of Nanomaterials · doi:10.1155/2016/1087250 · Cited by 265
Metadata
- Authors
- Saha, R. N., Vasanthakumar, S., Bende, G., & Snehalatha, M.
- Venue
- Molecular Membrane Biology
- Publisher
- Informa UK Limited
- Published
- 2010-10
- Volume
- 27
- Issue
- 7
- Pages
- 215-231
- ISSN
- 0968-7688 (ISSN-L)
- 1464-5203
- OpenAlex
- W1999526725
- Cited by
- 163
- References
- 4
- FWCI
- 3.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticulate drug delivery systems for cancer chemotherapy. https://app.cochat.ai/papers/10.3109/09687688.2010.510804
- The paper
- Saha, R. N., Vasanthakumar, S., Bende, G., & Snehalatha, M. (2010). Nanoparticulate drug delivery systems for cancer chemotherapy. Molecular Membrane Biology. https://doi.org/10.3109/09687688.2010.510804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.